News

event

Aug 30, 2024

Event

Shasqi CEO, José Mejía Oneto, joining panel at LSX USA World Congress on September 11th, Boston

event

Aug 29, 2024

Event

Shasqi VP of Research Travis Biechele, PhD, presenting at ADC & Radiopharmaceuticals Pharma & Biotech Partner summit in Boston on September 9th

conference

Jun 1, 2024

2024 - ASCO

Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024

conference

Apr 10, 2024

2024 - AACR

Improving anti-tumor efficacy by modulating a separate HER2 activator and an MMAE payload and reuniting both through click chemistry

conference

Apr 10, 2024

2024 - AACR

A click chemistry-based HER2 targeting agent activates a decoupled MMAE payload making it highly differentiated in efficacy and safety than ADCs

conference

Apr 10, 2024

2024 - AACR

Tumor targeted activation of an attenuated exatecan protodrug through Click Chemistry demonstrates efficacy in murine tumor studies

conference

Apr 10, 2024

2024 - AACR

Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry

conference

Apr 8, 2024

2024 - AACR

Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent

press

Apr 5, 2024

Press Release

Shasqi to Present Data on Novel Tumor-Targeted Drug Activation Technology at 2024 American Association for Cancer Research (AACR) Annual Meeting

conference

Mar 17, 2024

2024 - ACS

MMAE payload uncoupled from HER2 targeting agent is selectively activated at tumors through click chemistry in vivo

press

Mar 11, 2024

Press release

Shasqi Appoints Travis Biechele, Ph.D. as VP of Research to Lead Pipeline Development

press

Mar 5, 2024

Press release

Shasqi to Present New Data at 2024 World ADC London Conference